Scilex Holding

NASDAQ: SCLX · Real-Time Price · USD
5.08
0.34 (7.17%)
At close: May 01, 2025, 3:25 PM
7.17%
Bid 5.05
Market Cap 35.27M
Revenue (ttm) 56.59M
Net Income (ttm) -72.81M
EPS (ttm) -21.35
PE Ratio (ttm) -0.24
Forward PE 67.14
Analyst Buy
Ask 5.13
Volume 159,047
Avg. Volume (20D) 77,581
Open 4.74
Previous Close 4.74
Day's Range 4.61 - 5.15
52-Week Range 3.60 - 80.50
Beta 1.05

About SCLX

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural i...

Sector Healthcare
IPO Date Mar 5, 2021
Employees 115
Stock Exchange NASDAQ
Ticker Symbol SCLX
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for SCLX stock is "Buy." The 12-month stock price forecast is $455, which is an increase of 8856.69% from the latest price.

Stock Forecasts
2 weeks ago
-21.6%
Scilex Holding shares are trading lower after the ... Unlock content with Pro Subscription
4 weeks ago
+25.27%
Scilex Holding shares are trading higher. D. Boral Capital maintained a Buy rating on the stock.